Literature DB >> 10899654

Variants of the long control region of human papillomavirus type 16.

K Kurvinen1, M Yliskoski, S Saarikoski, K Syrjänen, S Syrjänen.   

Abstract

Expression of the human papillomavirus (HPV) E6 and E7 oncogenes is regulated on the transcriptional level by specific protein-binding sites contained in the viral long control region (LCR). Sequence changes within the LCR region may have an impact on the transcription of viral oncogenes, possibly resulting in differences in the oncogenic potential of the virus. The present study was designed to determine the sequence variability of the LCR of HPV 16 and to assess whether certain LCR variants do correlate with the clinical outcome of the disease of the uterine cervix. The entire LCR segment of HPV 16 was analysed from 37 cervical biopsy specimens derived from 28 women included in the Kuopio long-term prospective follow-up study. The LCR sequence was identical with the reference sequence in six HPV 16 isolates. Overall, 14 different HPV 16 LCR variants were identified. One of the variants showed sequence variation typical of the Asian-American variant lineage of HPV 16, and all the other variants appeared to belong to the European variant group. The European variants exhibited low genetic diversity, and only five of these LCR variants contained nucleotide changes involving known or proposed binding sites for transcription factors. The variants with changes at nucleotide positions 7193 and 7521 was the most prevalent, accounting for almost 37% of infections. This variant (7193; 7521) has been previously demonstrated to have similar transcriptional activity compared with the reference isolate by Veress and colleagues J Gen Virol 1999, 80, 1035-1043. The reference isolate, variant (7193; 7521) and variants with changes within transcription factor binding sites accounted for most of the infections, and no significant differences were found in the comparison of the distribution of these different LCR isolates in cases where the disease showed progression to severe cervical intraepithelial neoplasia (CIN) or carcinoma in situ (CIS). Notably, both the reference isolate and variant (7193; 7521) were also closely associated with infections showing more aggressive behaviour. According to the present findings, in European HPV 16 isolates, intratype genetic variation of the LCR region does not seem to be commonly responsible for differences in the pathogenicity of the virus and thereby for a risk of progressive infections.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899654     DOI: 10.1016/s0959-8049(00)00121-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique.

Authors:  Panu Peitsaro; Bo Johansson; Stina Syrjänen
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Human papillomavirus type 16 variant analysis of E6, E7, and L1 [corrected] genes and long control region in [corrected] cervical carcinomas in patients in northeast China.

Authors:  Qinglong Shang; Yan Wang; Yong Fang; Lanlan Wei; Sijia Chen; Yuhui Sun; Baoxin Li; Fengmin Zhang; Hongxi Gu
Journal:  J Clin Microbiol       Date:  2011-05-18       Impact factor: 5.948

3.  Upstream regulatory region alterations found in human papillomavirus type 16 (HPV-16) isolates from cervical carcinomas increase transcription, ori function, and HPV immortalization capacity in culture.

Authors:  Michael J Lace; Christina Isacson; James R Anson; Attila T Lörincz; Sharon P Wilczynski; Thomas H Haugen; Lubomír P Turek
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

4.  A non-radioactive PCR-SSCP analysis allows to distinguish between HPV 16 European and Asian-American variants in squamous cell carcinomas of the uterine cervix in Colombia.

Authors:  Pablo Moreno-Acosta; Mónica Molano; Antonio Huertas; Myriam Sánchez de Gómez; Alfredo Romero; Mauricio González; María Mercedes Bravo; Alejandro García-Carrancá
Journal:  Virus Genes       Date:  2008-05-30       Impact factor: 2.332

5.  Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in north India.

Authors:  Shailja Pande; Neeraj Jain; Bhupesh K Prusty; Suresh Bhambhani; Sanjay Gupta; Rajyashri Sharma; Swaraj Batra; Bhudev C Das
Journal:  J Clin Microbiol       Date:  2008-01-16       Impact factor: 5.948

6.  Entire genome characterization of human papillomavirus type 16 from infected Thai women with different cytological findings.

Authors:  Woradee Lurchachaiwong; Pairoj Junyangdikul; Sunchai Payungporn; Jira Chansaenroj; Pichet Sampathanukul; Damrong Tresukosol; Wichai Termrungruanglert; Apiradee Theamboonlers; Yong Poovorawan
Journal:  Virus Genes       Date:  2009-05-03       Impact factor: 2.332

7.  Variants of the long control region and the E6 oncogene in European human papillomavirus type 16 isolates: implications for cervical disease.

Authors:  C Kämmer; M Tommasino; S Syrjänen; H Delius; U Hebling; U Warthorst; H Pfister; I Zehbe
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

Review 8.  The Relationship between Estrogen-Related Signaling and Human Papillomavirus Positive Cancers.

Authors:  Claire D James; Iain M Morgan; Molly L Bristol
Journal:  Pathogens       Date:  2020-05-22

9.  Association of Human Papillomavirus Type 16 Long Control Region Variations with Cervical Cancer in a Han Chinese Population.

Authors:  Shuying Dai; Chuanyin Li; Zhiling Yan; Ziyun Zhou; Xia Wang; Jun Wang; Le Sun; Li Shi; Yufeng Yao
Journal:  Int J Med Sci       Date:  2020-03-26       Impact factor: 3.738

10.  Distribution of human papillomavirus genotypes in women with high-grade cervical intraepithelial lesions and cervical carcinoma and analysis of human papillomavirus-16 genomic variants.

Authors:  Magdalena Karadža; Snježana Židovec Lepej; Ana Planinić; Ivana Grgić; Ante Ćorušić; Pavao Planinić; Mario Ćorić; Lea Hošnjak; Kristina Fujs Komloš; Mario Poljak; Adriana Vince
Journal:  Croat Med J       Date:  2021-02-28       Impact factor: 1.351

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.